psoriasis

April Armstrong, MD, MPH, Dermatology Week 2022

Conference Coverage

Novel Topical PDE-4 Inhibitors For Plaque Psoriasis, Atopic Dermatitis, and Seborrheic Dermatitis

05/12/2022

Riya Gandhi, MA, Associate Editor

On the first day of Dermatology Week 2022, April Armstrong, MD, MPH, opened her session by noting, “There are common unmet needs in inflammatory skin diseases and that created opportunities for new well tolerated and effective topical...

On the first day of Dermatology...

05/12/2022

The Dermatologist

Conference Coverage

The Impact of IMID Treatment on COVID-19 Risk

04/21/2022

Riya Gandhi, MA, Associate Editor

Joel M. Gelfand, MD, MSCE, kicked off the session by saying, “In spring 2020, COVID toes were reported to occur 1 to 4 weeks post onset of COVID-19 symptoms.”

Joel M. Gelfand, MD, MSCE,...

04/21/2022

The Dermatologist

News

Body Composition Associated with Liver Fibrosis Development in Patients With Psoriasis

11/11/2021

Lisa Kuhns, PhD

For patients with psoriasis, body composition is associated with nonalcoholic hepatic fibrosis in both genders, but anthropometric data should be assessed differently in men and women.

For patients with psoriasis,...

11/11/2021

The Dermatologist

News

PsA Risk Highest in Patients With Severe Psoriasis

09/22/2021

Lauren Mateja, Managing Editor

Lauren Mateja, Managing Editor ...

A recent study published in Journal of the American Academy of Dermatology concluded that the risk of psoriatic arthritis (PsA) increases with psoriasis severity, with patients with severe psoriasis having the highest risk of PsA. Merola...

A recent study published in...

09/22/2021

The Dermatologist

Poll

Factors When Starting a New Biologic for Psoriasis

06/06/2021

The Dermatologist

FDA Alerts

New FDA Approval to Treat Moderate to Severe Pediatric Psoriasis

06/01/2021

Lauren Mateja, Managing Editor

The FDA announced approval of secukinumab, an IL-17 inhibitor, for the treatment of moderate to severe plaque psoriasis in patients aged 6 years and older. The approved dosing is 75 mg or 150 mg, dependent on the child’s weight at dosing...

The FDA announced approval of...

06/01/2021

The Dermatologist

Partner Approved

The Psoriasis and Comorbidity Series: Inflammatory Bowel Disease

12/14/2020

Kristi Hawley, DO

Psoriasis has a known association with inflammatory bowel disease, including Crohn disease and ulcerative colitis. Dermatologists should keep the association in mind when treating their patients with psoriasis.

Psoriasis has a known...

12/14/2020

The Dermatologist

Online Exclusive

Can Halobetasol Have An Impact For Treating Psoriasis?

12/29/2019

By Tracey C. Vlahovic, DPM, FFPM, RCPS (Glasg)

By Tracey C. Vlahovic, DPM, FFPM, RCP...

Psoriasis can commonly appear on the lower extremities but much of the literature does not address this condition in this anatomic area. Accordingly, this author shares three recent studies and their results regarding a novel formulization of...

Psoriasis can commonly appear on...

12/29/2019

Podiatry Today

Feature

Current And Emerging Modalities For Psoriasis

10/08/2018

By Tracey C. Vlahovic, DPM, FFPM, RCPS (Glasg), Michael Romani, BS, Garrett Biela, BS, Kalen Farr ,BS, Ryan Lazar, BS, Marcus Duval, BS, and Victoria Trovillion, MS

By Tracey C. Vlahovic, DPM, FFPM, RCP...

Palmoplantar psoriasis can be a particularly devastating condition, given the condition’s negative effect on quality of life. These authors provide a stepwise guide to therapy, progressing from topical steroids to phototherapy to biologics...

Palmoplantar psoriasis can be a...

10/08/2018

Podiatry Today

Case Report and Brief Review

Efficacy of Natural Honey Versus Fluticasone Propionate in Mild Psoriasis: A Case Study

09/28/2017

Bassil Kherallah

Zaghloul Gouda

Hashim Mohamed

09/28/2017

Wounds